Evidence map›Paper›PMID 29399381›Full record

ArticleJournal of clinical & cellular immunology2017

Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective.

John Matthew Bryant, Mollie Bouchard, Azizul Haque

Abstract read
In one paragraph

Article in Journal of clinical & cellular immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Overview of fungal terpene synthases and their regulation.World journal of microbiology & biotechnology · 2023
    Review
  7. Anticancer and Antioxidant Activities inInternational journal of molecular sciences · 2022
    Article
  8. Nutritional Profile and Health Benefits ofFoods (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Frontiers in pharmacology · 2022
    Review
  11. Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

John Matthew BryantDepartment of Microbiology and Immunology, and Hollings Cancer Center, Medical University of South Carolina, USA.
Mollie BouchardDepartment of Microbiology and Immunology, and Hollings Cancer Center, Medical University of South Carolina, USA.
Azizul HaqueDepartment of Microbiology and Immunology, and Hollings Cancer Center, Medical University of South Carolina, USA.

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7M
Disruption of HLA Class II-Mediated Immune Recognition of B-Cell LymphomasR01CA129560 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HAQUE, AZIZUL · 2009 to 2013
$1.5M
NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA129560
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnticancerCell deathGanoderic acid-DM (GA-DM)Ganoderma lucidumT cells

Identifiers

PMID29399381
PMCPMC5795599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.